Claims for Patent: 7,482,327

Summary for Patent: 7,482,327

Title:	Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules
Abstract:	The present invention provides use of soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig in the treatment of immune disorders associated with graft transplantation.
Inventor(s):	Hagerty; David (Pennington, NJ), Rusnak; James (Newtown, PA)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	11/399,666
Patent Claims:	1. A method for treating an immune disorder associated with graft transplantation comprising administering to a subject an effective dose of a CTLA4 mutant molecule comprising an extracellular domain of CTLA4 as shown in SEQ ID NO:8 beginning with alanine at position 26 or methionine at position 27 and ending with aspartic acid at position 150, or a portion thereof, wherein in the extracellular domain or portion thereof an alanine at position 55 is substituted with a tyrosine, and a leucine at position 130 is substituted with a glutamic acid and wherein the administration regimen comprises an early phase regimen, wherein the early phase regimen ranges from the first 3 to 6 months post-transplantation and involves administration on day 1, week 2 visit, week 4 visit, week 8 visit and week 12 visit, and wherein the administration regimen further comprises a maintenance phase regimen wherein the maintenance phase regimen begins after the early phase regimen ends and involves administration of CTLA4 mutant molecule that is not more frequent than monthly. 2. A method for treating an immune disorder associated with graft transplantation comprising administering to a subject an effective dose of a CTLA4 mutant molecule comprising: (a) an amino acid sequence beginning with methionine at position 27 and ending with aspartic acid at position 150 of SEQ ID NO:4, or (b) an amino acid sequence beginning with alanine at position 26 and ending with aspartic acid at position 150 of SEQ ID NO:4 and wherein the CTLA4 mutant molecule administration regimen comprises an early phase regimen, wherein the early phase regimen ranges from the first 3 to 6 months post-transplantation and involves administration on day 1, week 2 visit, week 4 visit, week 8 visit and week 12 visit, and wherein the administration regimen further comprises a maintenance phase regimen wherein the maintenance phase regimen begins after the early phase regimen ends and involves administration of CTLA4 mutant molecule that is not more frequent than monthly. 3. The method according to claim 1 or 2 wherein the early phase administration regimen comprises administration of CTLA4 mutant molecule on day 5. 4. The method according to claim 3 wherein the early phase administration regimen comprises administration of CTLA4 mutant molecule on week 6 visit, week 10 visit, month 4 visit, month 5 visit and month 6 visit. 5. The method according to claim 3 or 4 wherein the effective dose of CTLA4 mutant molecule during the early phase is about 10 mg/kg weight of the subject. 6. The method according to claim 1 or 2 wherein the effective dose of CTLA4 mutant molecule during the maintenance phase is about 5 mg/kg weight. 7. The method according to claim 1 or 2 wherein the effective dose of the CTLA4 mutant molecule is about 10 mg/kg weight of the subject with an administration regimen comprising administration on days 1, 15, 29, 57, 85 and 5 gm/kg monthly thereafter. 8. The method according to claim 1 or 2 wherein the effective dose of the CTLA4 mutant molecule is about 10 mg/kg weight of the subject with an administration regimen comprising administration on days 1, 5, 15, 29, 57, 85 and 5 mg/kg monthly thereafter. 9. The method according to claim 1 or 2 wherein the effective dose of the CTLA4 mutant molecule is about 10 mg/kg weight of the subject with an administration regimen comprising administration on days 1, 5, 15, 29, 43, 57, 71, 85, 113, 141, 169 and 5 mg/kg monthly thereafter. 10. The method according to claim 1 or 2 wherein the immune disorders associated wit graft transplantation comprises solid organ, tissue and/or cell transplant rejection. 11. The method according to claim 10 wherein the immune disorders associated with graft transplantation comprises kidney transplant rejection. 12. The method according to claim 1 or 2 wherein the CTLA4 mutant molecules further comprise an amino acid sequence which alters the solubility, affinity and/or valency of the soluble CTLA4 mutant molecule. 13. The method according to claim 12, wherein the amino acid sequence which alters the solubility, affinity and/or valency comprises an immunoglobulin moiety. 14. The method according to claim 13, wherein the immunoglobulin moiety is an immunoglobulin constant region or portion thereof 15. The method according to claim 14, wherein the immunoglobulin constant region or portion thereof is mutated to reduce effector function. 16. The method according to claim 14 wherein the immunoglobulin constant region or portion thereof comprises a hinge, CH2 and CH3 regions of a human or monkey immunoglobulin molecule. 17. The method according to claim 15 wherein the immunoglobulin constant region or portion thereof comprises a hinge, CH2 and CH3 regions of a human or monkey immunoglobulin molecule. 18. The method according to claim 13, wherein the immunoglobulin comprises an amino acid sequence which begins with glutamic acid at position +152 and ends with lysine at position +383, as shown in SEQ ID NO:4. 19. The method according to claims 1 or 2 further comprising a junction amino acid residue and an immunoglobulin, where the junction amino acid residue is located between the amino acid sequence which ends with aspartic acid at position +150 and the immunoglobulin. 20. The method according to claim 1 or 2 wherein said CTLA4 mutant molecule is co-administered with at least one of the agents selected from the group consisting of basiliximab , daclizumab, anti-thymocyte globulin, cyclosporine, tacrolimus, mycophenolate mofetil (MMF), mycophenolic acid, azathioprine, muromonab, rituximab, sirolimus, everolimus, fingolimod, Jak-3, betamethasone, budesonide, cortisol, cortisone, dexamethasone, hydrocritisone, methyiprednisolone, prednisolone, prednisone and triameinolone. 21. A method according to claim 1 or 2 wherein development and/or progression of an outcome selected from the group consisting of chronic allograft neuropathy (CAN), hyperlipidemia, hypertension, diabetes, hirsuitism, alopecia, gingival hyperplasia, tremor, neurotoxicity and bone loss is reduced. 22. The method according to claim 1 or 2 further comprising a target trough serum concentration of the CTLA4 mutant molecule between about 3 .mu.g/ml and about 30 .mu.g/ml. 23. A method for treating an immune disorder associated with graft transplantation comprising administering to a subject an effective dose of a CTLA4 mutant molecule comprising: (a) an amino acid sequence beginning with methionine at position 27 and ending with lysine at position +357 or glycine at position +356 of FIG. 7, or (b) an amino acid sequence beginning with alanine at position 26 and ending with lysine at position +357 or glycine at position +356 of FIG. 7 and wherein the CTLA4 mutant molecule administration regimen comprises an early phase regimen, wherein the early phase regimen ranges from the first 3 to 6 months post-transplantation and involves administration on day 1, week 2 visit, week 4 visit, week 8 visit and week 12 visit,, and wherein the administration regimen further comprises a maintenance phase regimen wherein the maintenance phase regimen begins after the early phase regimen ends and involves administration of CTLA4 mutant molecule that is not more frequent than monthly. 24. The method according to claim 1, 2 or 23 wherein the CTLA4 mutant molecule is co-administered concomitantly or sequentially with agents comprising basiliximab and MMF. 25. The method according to claim 1, 2 or 23 wherein the CTLA4 mutant molecule is co-administered concomitantly or sequentially with agents comprising daclizumab and sirolimus.

Details for Patent 7,482,327

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2025-04-06
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2025-04-06
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	12/10/1997		2025-04-06
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	05/12/1998		2025-04-06